Oncotelic Therapeutics, Inc.
Immunotherapy drug candidates and molecular nanomedicine platform using AI-guided drug development
- Sector
- Biotech
- Headquarters
- AGOURA HILLS, CA
- Latest Form D
- $275K, Dec 2025
- Total capital
- $40.3M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $40.3M
- 7 Form D · last Dec 2025
- 10 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 1 pending · first 2022
- Rank in peer group#481 of 1462
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 7th filing$275K
- Offering registeredForm D · SEC · 6th filing$5M
- Private capital raisedForm D · SEC · 5th filing$2M
- Private capital raisedForm D · SEC · 4th filing$27M
- Private capital raisedForm D · SEC · 3rd filing$600K
- Private capital raisedForm D · SEC · 2nd filing$2.9M
- Private capital raisedForm D · SEC · 1st filing$7.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3390 | OPUS GENETICS INC. | — | $46.9M |
| 3391 | CERo Therapeutics, Inc. | — | $44.6M |
| 3392 | Forte Biosciences | — | $44.1M |
| 3393 | Oncotelic Therapeutics, Inc. | — | $40.3M |
| 3394 | ADVANTAGENE, INC | — | $35.9M |
| 3395 | Allarity Therapeutics, Inc. | — | $26.9M |
| 3396 | OTHRAM, INC. | — | $31.7M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- David ChaplinDirector · Executive Officer
- Seymour FeinExecutive Officer
- Roy FicklingDirector
- Mark KesselDirector
- Peter LangeckerExecutive Officer
- Matthew LoarExecutive Officer
- Anthony MaidaExecutive Officer
- James MurphyExecutive Officer
Show all 21 people
- Chuho ParkExecutive Officer
- Chulho ParkExecutive Officer
- Simon PedderDirector
- Donald ReynoldsDirector
- Bobby Sandage, Jr.Director
- Saran SaundExecutive Officer
- William SchwietermanDirector · Executive Officer
- Amit ShahExecutive Officer
- William ShieblerDirector
- Vuong TrieuDirector · Executive Officer
- VUONG TRIEUDirector · Executive Officer
- Fatih UckunExecutive Officer
- Alastair WoodDirector
Patents
- Use Of Vdas To Enhance Immunomodulating Therapies Against Tumorsapplication
- Use Of Vdas To Enhance Immunomodulating Therapies Against Tumorsgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.